853 ACTM-838: a microbial-based immunotherapy that delivers combination IL-15 + engineered STING to tumor-resident APCs after IV dosing in T-cell excluded solid tumors

MLA

Laura Glickman, et al. “853 ACTM-838: A Microbial-Based Immunotherapy That Delivers Combination IL-15 + Engineered STING to Tumor-Resident APCs after IV Dosing in T-Cell Excluded Solid Tumors.” Journal for ImmunoTherapy of Cancer, vol. 9, no. Suppl 2, Nov. 2021. EBSCOhost, https://doi.org/10.1136/jitc-2021-SITC2021.853.

APA

Laura Glickman, Michele Ardolino, Haixing Kehoe, Alexandre Iannello, Keith Cheung, Bret Peterson, Marie Marotel, Sara Tribble, Hailey He, Jonathan Hodgins, Christopher Rae, & Christopher Thanos. (2021). 853 ACTM-838: a microbial-based immunotherapy that delivers combination IL-15 + engineered STING to tumor-resident APCs after IV dosing in T-cell excluded solid tumors. Journal for ImmunoTherapy of Cancer, 9(Suppl 2). https://doi.org/10.1136/jitc-2021-SITC2021.853

Chicago

Laura Glickman, Michele Ardolino, Haixing Kehoe, Alexandre Iannello, Keith Cheung, Bret Peterson, Marie Marotel, et al. 2021. “853 ACTM-838: A Microbial-Based Immunotherapy That Delivers Combination IL-15 + Engineered STING to Tumor-Resident APCs after IV Dosing in T-Cell Excluded Solid Tumors.” Journal for ImmunoTherapy of Cancer 9 (Suppl 2). doi:10.1136/jitc-2021-SITC2021.853.